Clinical Trial Update: Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Surufatinib in recurrent/metastatic head and neck adenocarcinomas (salivary gland origin) with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancers
• Salivary Gland Cancer

Drugs mentioned

• Surufatinib (Surufatinib)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Head and Neck Cancers - Salivary Gland | Phase 2 | Status: UNKNOWN